Changes in the Activity of Connective Tissue Matrix Enzymes in the Metabolic Syndrome

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2012 Feb 1

PMID 22291799

Citations 7

Authors

Jolanta Mieczkowska

Jerzy Mosiewicz

Wojciech Barud

Wojciech Kwasniewski

Affiliations

Soon will be listed here.

Abstract

Introduction: Early atherosclerotic changes in the endothelium associated with metabolic syndrome are generated with the participation of inflammatory cells, cytokines and enzymes of the extracellular matrix. The study is aimed at a comparison between the activity of inflammatory agents, tumour necrosis factor α (TNF-α) and the enzymes of the connective tissue matrix in the blood of healthy female patients as well as those suffering from the metabolic syndrome.

Material And Methods: The examination included 35 women with metabolic syndrome (MS). The control group (C) comprised 35 healthy women. Lipidogram, C-reactive protein level (CRP), fasting glucose level (FGL), matrix metalloproteinase (MMP)-8 and -9 activity, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TNF-α levels in blood were determined.

Results: As compared with the control group, the level of inflammatory factors and the activity of extracellular matrix enzymes in the metabolic syndrome were statistically higher (p < 0.05) and concerned the following parameters: TNF-α (pg/ml): MS 6.59 ±3.18, C 4.78 ±2.91; CRP (mg/dl): MS 2.18 ±2.04, C 1,26 ±1.35; TIMP-1 (ng/ml): MS 265.5 ±2.9, C 205.4 ±72.6; MMP-9 (ng/ml): MS 198.2 ±138.6, C 138.6 ±116.1. Statistically significant correlations were also found between TIMP-1 and the following factors: BMI (R = 0.400, p < 0.001), waist/hip ratio (WHR) (R = 0.278, p < 0.05), waistline (R = 0.417, p < 0.001), FGL (R = 0.290, p < 0.05), HDL cholesterol (R = -0.253, p < 0.05) and triglycerides (R = 0.269, p < 0.05).There were positive correlations of MMP-9 with FGL (R = 0.446, p < 0.001) and waistline (R = 0.260, p < 0.05); MMP-8 with FGL (R = 0.308, p < 0.05); and CRP with BMI (R = 0.370, p < 0.01), WHR (R = 0.325, p < 0.01) and waistline (R = 0.368, p < 0.01).

Conclusions: Metabolic syndrome is connected with higher activity of cytokines (TNF-α), inflammatory markers (CRP) and matrix enzymes (MMP-9, MMP-8, TIMP-1).

Citing Articles

Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice.

Tiyerili V, Becher U, Camara B, Yildirimturk C, Aksoy A, Kebschull M Arch Med Sci. 2015; 11(4):877-85.

PMID: 26322101 PMC: 4548041. DOI: 10.5114/aoms.2015.53309.

Effect of elastin-derived peptides on the production of tissue inhibitor of metalloproteinase-1, -2, and -3 and the ratios in various endothelial cell lines.

Siemianowicz K, Likus W, Francuz T, Garczorz W Exp Ther Med. 2015; 9(6):2245-2250.

PMID: 26136968 PMC: 4473351. DOI: 10.3892/etm.2015.2429.

Significance of impaired serum gelatinases activities in metabolic syndrome.

Yadav S, Singh M, Dwivedi P, Mandal R, Usman K, Khattri S Toxicol Int. 2014; 21(1):107-11.

PMID: 24748744 PMC: 3989907. DOI: 10.4103/0971-6580.128818.

Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.

Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, Mueller C Arch Med Sci. 2014; 10(1):154-60.

PMID: 24701228 PMC: 3953984. DOI: 10.5114/aoms.2014.40742.

Ginkgo suppresses atherosclerosis through downregulating the expression of connexin 43 in rabbits.

Wei J, Wang X, Gong H, Shi Y, Zou Y Arch Med Sci. 2013; 9(2):340-6.

PMID: 23671447 PMC: 3648825. DOI: 10.5114/aoms.2013.34416.

References

Owen C, Hu Z, Lopez-Otin C, Shapiro S . Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004; 172(12):7791-803. DOI: 10.4049/jimmunol.172.12.7791. View

Pasqui A, Di Renzo M, Bova G, Maffei S, Pompella G, Auteri A . Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med. 2006; 6(1):38-44. DOI: 10.1007/s10238-006-0092-9. View

Glowinska-Olszewska B, Urban M . Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism. 2007; 56(6):799-805. DOI: 10.1016/j.metabol.2007.01.011. View

Dollery C, McEwan J, Henney A . Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77(5):863-8. DOI: 10.1161/01.res.77.5.863. View

Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F . Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005; 69(9):1035-40. DOI: 10.1253/circj.69.1035. View

Ikonomidis J, Jones J, Barbour J, Stroud R, Clark L, Kaplan B . Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007; 133(4):1028-36. DOI: 10.1016/j.jtcvs.2006.10.083. View

Camejo G, Hurt-Camejo E, Olsson U, Bondjers G . Lipid mediators that modulate the extracellular matrix structure and function in vascular cells. Curr Atheroscler Rep. 2000; 1(2):142-9. DOI: 10.1007/s11883-999-0010-1. View

Tayebjee M, Nadar S, MacFadyen R, Lip G . Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens. 2004; 17(9):770-4. DOI: 10.1016/j.amjhyper.2004.06.023. View

Nanni S, Melandri G, Hanemaaijer R, Cervi V, Tomasi L, Altimari A . Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res. 2007; 149(3):137-44. DOI: 10.1016/j.trsl.2006.09.001. View

10.

Derosa G, DAngelo A, Ciccarelli L, Piccinni M, Pricolo F, Salvadeo S . Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006; 13(3):227-31. DOI: 10.1080/10623320600780942. View

11.

Watanabe N, Ikeda U . Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep. 2004; 6(2):112-20. DOI: 10.1007/s11883-004-0099-1. View

12.

Tziakas D, Chalikias G, Hatzinikolaou H, Parissis J, Papadopoulos E, Trypsianis G . Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol. 2003; 92(2-3):169-75. DOI: 10.1016/s0167-5273(03)00084-6. View

13.

Bonetti P, Lerman L, Lerman A . Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23(2):168-75. DOI: 10.1161/01.atv.0000051384.43104.fc. View

14.

ARAI K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T . Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 1990; 59:783-836. DOI: 10.1146/annurev.bi.59.070190.004031. View

15.

Sabatine M, Morrow D, de Lemos J, Gibson C, Murphy S, Rifai N . Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002; 105(15):1760-3. DOI: 10.1161/01.cir.0000015464.18023.0a. View

16.

Lee S, Song K, Shin D, Ahn S, Ha E, Kim D . Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract. 2005; 69(2):175-9. DOI: 10.1016/j.diabres.2004.12.010. View

17.

Pawlak K, Pawlak D, Mysliwiec M . Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress. Cytokine. 2005; 31(1):18-24. DOI: 10.1016/j.cyto.2004.12.020. View

18.

Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-Maj E . Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis. 2003; 14(6):431-8. DOI: 10.1097/00019501-200309000-00003. View

19.

Tayebjee M, Nadar S, Blann A, Beevers D, MacFadyen R, Lip G . Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004; 17(9):764-9. DOI: 10.1016/j.amjhyper.2004.05.019. View

20.

Goncalves F, Jacob-Ferreira A, Gomes V, Casella-Filho A, Chagas A, Marcaccini A . Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta. 2009; 403(1-2):173-7. DOI: 10.1016/j.cca.2009.02.013. View